Ivacaftor vs VX-828
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Cystic Fibrosis
Shared mechanism: CFTR · full Cystic Fibrosis pipeline
Ivacaftor · Kalydeco
Marketed by Vertex Pharmaceuticals
NCT00909532 · Phase 3 · completed
The study was randomized and quadruple-blinded, compared ivacaftor with placebo, and enrolled 167 participants; its objective primary endpoint, percent-predicted FEV1, was met with a statistically significant treatment difference. However, the supplied registry record does not report a power or sample-size calculation, so the trial receives a moderate grade despite its otherwise strong design.
Reported efficacy
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) (met)
Result source: NCT00909727
VX-828
Developed by Vertex Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Cystic Fibrosis
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
VX-828: no structured comparison results are available for Cystic Fibrosis.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ivacaftor's landscape · VX-828's landscape